For most of Big Pharma, drug discounts have largely been about damage control. After months of tariff threats and talk of ...

The weight loss medicines are proving to be a test case for Robert F. Kennedy Jr., the health secretary, in straddling ...

Medicare beneficiaries will soon be able to get obesity and Type 2 diabetes drugs for a $50 copay. But there are some ...

Certain blockbuster obesity drugs will be available for as little as $149 per month and more Medicare enrollees will have ...

Pfizer noted it has completed its acquisition of all outstanding shares of the company’s common stock for $65.60 per share in ...

The president’s agreement with drug companies involves a range of prices, depending on dose, product and how you’re paying.

Pfizer is buying its way back into the obesity-drug game after fighting off a rival bid from Novo Nordisk to buy Metsera, ...

The White House may have struck a deal with Eli Lilly and Novo Nordisk last week to lower the costs of their weight loss ...

Weight-loss drug developer Zealand Pharma said it halted work on an early-stage obesity treatment candidate to focus on more promising programs, including one for which it teamed up with Swiss giant ...

Pfizer has signed a deal to purchase Metsera Inc., an obesity drugmaker in the development stage, after winning a bidding war ...

A White House deal with Eli Lilly & Co. and Novo Nordisk to lower the prices of their popular obesity medicines, Zepbound and ...

Eli Lilly and Novo Nordisk's competition in weight-loss drugs has affected thousands of jobs between Charlotte and Raleigh.